康泰生物终止与阿斯利康设立疫苗合资公司计划

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has decided to terminate its plan to establish a joint venture with AstraZeneca Investment (China) Co., Ltd. due to significant changes in the market environment and increased investment risks in the vaccine industry [1] Group 1: Joint Venture Details - The joint venture was initially planned to be established in March 2025, with both companies holding a 50% stake and a registered capital of approximately 345 million RMB, with a total investment of around 400 million USD [1] - The decision to terminate the joint venture was made after careful evaluation and friendly consultation among the parties involved, as the new vaccine industry investment risks were deemed too high [1] Group 2: Impact on Company Operations - As of now, the joint venture has not been established, and Kangtai Biological has not made any actual capital contributions [1] - The company stated that this termination will not have a significant impact on its existing business, financial status, or operational conditions [1] - Kangtai Biological will continue to pursue its strategy of "internal innovation + external expansion" and deepen its international business layout [1]